ライフサイエンスコーパス: chemotherapeutic

1 n breast cancer, increasing sensitivity to a chemotherapeutic.

2 luding both targeted as well as conventional chemotherapeutics.

3 w bacteria affect the C. elegans response to chemotherapeutics.

4 S-driven cancers are infamously resistant to chemotherapeutics.

5 the role of bacteria in the host response to chemotherapeutics.

6 l line exacerbated DNA damage in response to chemotherapeutics.

7 res in response to metabolic inhibitors, and chemotherapeutics.

8 pecific effects regulating the resistance to chemotherapeutics.

9 e rational design of alpha-tubulin targeting chemotherapeutics.

10 tance (MDR), being capable of effluxing many chemotherapeutics.

11 astasis and to increase tumor sensitivity to chemotherapeutics.

12 f unique molecules including highly valuable chemotherapeutics.

13 meter-sized particle that can be loaded with chemotherapeutics.

14 nge of clinical and preclinical stage cancer chemotherapeutics.

15 ncer that resists efforts to identify better chemotherapeutics.

16 e-of-day may alter inflammatory responses to chemotherapeutics.

17 atory axis, conferring resistance to various chemotherapeutics.

18 resistance to a broad range of DNA-damaging chemotherapeutics.

19 tin, are some of the most widely used cancer chemotherapeutics.

20 ent blood-brain barrier (BBB) penetration of chemotherapeutics.

21 revealing a broad window for PfCRK4-targeted chemotherapeutics.

22 A multi-agent chemotherapeutic ablation admixture did not appear to si

23 y with animal tumor models, to confirm their chemotherapeutic activity in vivo.

24 us for future structure-based drug design of chemotherapeutics against malaria.

25 ion, and resistance to the colorectal cancer chemotherapeutic agent 5-fluorouracil.

26 duces the sensitivity of cancer cells to the chemotherapeutic agent 5-fluorouracil.

27 BNPs loaded with a potent chemotherapeutic agent [epothilone B (EB)] showed signif

28 ng the use of olaparib in combination with a chemotherapeutic agent and provides a foundation for fut

29 Cladribine was the most commonly used chemotherapeutic agent and was administered in 21 of 63

30 Notably, cotreatment of chemotherapeutic agent camptothecin enhanced LSD1 inhibi

31 ficacious and well-established anthracycline chemotherapeutic agent commonly used in the treatment of

32 id not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX) in a xenograft

33 nd on the sensitivity of cancer cells to the chemotherapeutic agent doxorubicin (DXR) and growth fact

34 2)-DNA adducts induced by treatment with the chemotherapeutic agent etoposide.

35 Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors

36 After the approval of cisplatin as a chemotherapeutic agent in 1978, several types of metal-b

37 Isolated limb perfusion (ILP) with the chemotherapeutic agent melphalan is an effective treatme

38 d heat stimulation) or by treatment with the chemotherapeutic agent paclitaxel (which induces hyperse

39 nduced by complete Freund's adjuvant and the chemotherapeutic agent paclitaxel in wild-type but not C

40 Here we show that the chemotherapeutic agent paclitaxel triggers CIPN by alter

41 ance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to c

42 Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that is widely used in cancer tre

43 n a mouse model of neuropathy induced by the chemotherapeutic agent vincristine.

44 Immunochemotherapy combines a chemotherapeutic agent with an immune-modulating agent a

45 Y-I2-BODIPY can act as an immune-stimulatory chemotherapeutic agent with potential applications in cl

46 Cisplatin is a particularly potent chemotherapeutic agent, but its use to treat GBM is limi

47 Doxorubicin (DOX), a common chemotherapeutic agent, impairs synaptic plasticity.

48 e results showed that MSNR could deliver the chemotherapeutic agent, MTX to tumor cells and induce ef

49 contemporaneous delivery of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX).

50 the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to exacerbate metastasis in mous

51 nal antibody to increase the efficacy of the chemotherapeutic agent, while reducing toxicity.

52 Cisplatin is a common and effective chemotherapeutic agent, yet it often causes permanent he

53 Thus, ATF3 in the host cells links a chemotherapeutic agent-a stressor-to immune modulation a

54 otherapy in PDAC cells through inhibition of chemotherapeutic agent-induced autophagy.

55 taxel, an important yet poorly water-soluble chemotherapeutic agent.

56 to reduce pain in patients treated with this chemotherapeutic agent.

57 al acne creams as well as being a first-line chemotherapeutic agent.

58 astuzumab and pertuzumab became resistant to chemotherapeutic agents (5-fluoruracil, carboplatin, cis

59 st), as well as pharmacologic assays against chemotherapeutic agents (half-maximal effective concentr

60 The efficacy of two front-line chemotherapeutic agents (paclitaxel and cisplatin) are d

61 exhibited distinct sensitivities toward drug chemotherapeutic agents and radiation as compared with t

62 CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk.

63 our cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, includin

64 Paclitaxel (PTX) is one of the most useful chemotherapeutic agents approved for several cancers, in

65 rodegenerative changes and a number of newer chemotherapeutic agents are being tested to ameliorate t

66 evented peripheral neuropathy induced by the chemotherapeutic agents dichloroacetate and paclitaxel o

67 Malaria control is heavily dependent on chemotherapeutic agents for disease prevention and drug

68 at sustained exposure of microtubule-binding chemotherapeutic agents in peripheral nerve tissues cann

69 ave important implications for the choice of chemotherapeutic agents in the treatment of Mdm2-overexp

70 clinically achievable doses of HRR-inducing chemotherapeutic agents in vitro and in vivo in a murine

71 However, insensitivity to these chemotherapeutic agents including cisplatin is common.

72 r than 3 g/dL, and receipt of no more than 2 chemotherapeutic agents independently predicted better s

73 r, the efficacy of nanoparticles loaded with chemotherapeutic agents is currently hampered by their f

74 The present study evaluated the effect of chemotherapeutic agents on exosome production and/or rel

75 To study the effects of chemotherapeutic agents on the hair follicle, a number o

76 ological malignancies, and the resistance to chemotherapeutic agents remains a major challenge to suc

77 e ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).

78 Our results indicate (a) chemotherapeutic agents stimulate exosome production or

79 in EpCAM(+) spheroids are more resistant to chemotherapeutic agents than 2D-cultured cells.

80 human cancer cells the ability to counteract chemotherapeutic agents that elicit cell death by damagi

81 , which would be an improvement over current chemotherapeutic agents that indiscriminately kill proli

82 d to antimicrobial resistance but also to be chemotherapeutic agents that may be allergenic and poten

83 ul method for an effective local delivery of chemotherapeutic agents to treatment of cancers.

84 geted carriers provide efficient delivery of chemotherapeutic agents to tumor tissue.

85 Mitomycin and platinum-based chemotherapeutic agents were used in 96 (72.2%) and 37 (

86 t a new approach to maximize the efficacy of chemotherapeutic agents while reducing dose-related toxi

87 HSP70-targeted therapy (but not chemotherapeutic agents) promoted apoptosis in RMS cells

88 hibited reduced proliferation, resistance to chemotherapeutic agents, and stem-like metabolic changes

89 chemoresistance in the AML cells exposed to chemotherapeutic agents, and this was reversed following

90 ificantly higher sensitivity to the standard chemotherapeutic agents, i.e., doxorubicin (DOX) and cyt

91 ion of those MDR tumor cells to conventional chemotherapeutic agents, including cisplatin, sorafenib,

92 However, in spite of effective chemotherapeutic agents, neuropathy and associated defor

93 ors, co-delivery of survivin inhibitors with chemotherapeutic agents, synchronous targeting of surviv

94 rs an attractive route of administration for chemotherapeutic agents, with the advantages of high dru

95 attractive target for new parasite-specific chemotherapeutic agents.

96 s and pathomechanisms of specific neurotoxic chemotherapeutic agents.

97 e as a defensive shield against conventional chemotherapeutic agents.

98 ry and academia towards the discovery of new chemotherapeutic agents.

99 ion with other tyrosine kinase inhibitors or chemotherapeutic agents.

100 that together cause inefficient delivery of chemotherapeutic agents.

101 dose-limiting side effect of many important chemotherapeutic agents.

102 DNA breaks caused by ionizing radiation and chemotherapeutic agents.

103 tic alterations or to screen the efficacy of chemotherapeutic agents.

104 nsitization of HCC cells toward conventional chemotherapeutic agents.

105 iology of cancer cells and their response to chemotherapeutic agents.

106 chanism to stress, including that induced by chemotherapeutic agents.

107 ing the brain against the effects of various chemotherapeutic agents.

108 Cs accounts for positive immunomodulation by chemotherapeutic agents.

109 y and can ultimately improve the efficacy of chemotherapeutic agents.

110 rs cytoprotection against stress stimuli and chemotherapeutic agents.

111 by death receptors or intrinsic apoptosis by chemotherapeutic agents.

112 t Jurkat cells during apoptotic responses to chemotherapeutic agents.

113 ic target, thus eliminating the need for any chemotherapeutic agents.

114 n modulating the response of cancer cells to chemotherapeutic and biological treatments and highlight

115 In response to the chemotherapeutic and DNA-demethylating agent 5-aza-deoxy

116 ferences in host gene expression between the chemotherapeutic and steroid models at the interface of

117 ess the spatial distribution of administered chemotherapeutics and metabolites with MALDI-imaging mas

118 With the advent of novel chemotherapeutics and targeted molecular, cellular, and

119 emically modified liposomes for loading with chemotherapeutics and targeting them for the transporter

120 CLs) are generated by endogenous sources and chemotherapeutics, and pose a threat to genome stability

121 The chemotherapeutic anthracycline metabolite doxorubicinol

122 7) and is effective in predicting a range of chemotherapeutic, antiviral and antibiotic resistance mu

123 r designing prospective drugs for photo- and chemotherapeutic applications.

124 maintain genomic stability is an attractive chemotherapeutic approach.

125 of epigenetic, cellular differentiation, and chemotherapeutic approaches against triple-negative brea

126 is approach can potentially improve existing chemotherapeutic approaches.

127 Sorafenib is the only chemotherapeutic approved for treatment of advanced hepa

128 responding to the threat; new knowledge and chemotherapeutics are being created to safeguard our fut

129 Single-nanoparticle (NP) combination chemotherapeutics are quickly emerging as attractive alt

130 adiation into heat, causing the release of a chemotherapeutic as well as thermally induced cell damag

131 used for development of novel DNA-targeting chemotherapeutics based on benzo[c]quinolizinium derivat

132 synergy between PDT and the standard-of-care chemotherapeutic carboplatin that evolved over time.

133 These NCP particles contain high payloads of chemotherapeutics cisplatin or cisplatin plus gemcitabin

134 omplication rates, and whether a multi-agent chemotherapeutic cocktail could increase the rate of com

135 delivery sequence of microRNA inhibitor and chemotherapeutic compounds achieve distinct therapeutic

136 entify Food and Drug Administration-approved chemotherapeutic compounds possessing synergistic activi

137 presence of nontargeted chemicals including chemotherapeutics consistent with a local hospital waste

138 favorable subtypes of AML generally receive chemotherapeutic consolidation, although recent studies

139 -pyrazolo[4,3-c]quinoline (42) combined with chemotherapeutic CPT-11 treatment prevented CPT-11-induc

140 Many antibiotics, chemotherapeutics, crop protection agents and food prese

141 ombining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benef

142 Next, we applied these findings to improve chemotherapeutic delivery by augmenting the parent drug'

143 promising nanoplatform for integrin targeted chemotherapeutic delivery to lung cancer.

144 glioblastoma response to treatment with the chemotherapeutic DNA-damaging agent temozolomide.

145 ing this system for targeted delivery of the chemotherapeutic docetaxel, we showed that bone tumor bu

146 onstrate the loading of two model drugs: the chemotherapeutic doxorubicin and the antibiotic vancomyc

147 ee delivery of a predetermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the b

148 By achieving higher chemotherapeutic drug concentrations in target lesions,

149 pre-treatment with N6L efficiently improved chemotherapeutic drug delivery and increased the antitum

150 ow) and potentially enhance co-administrated chemotherapeutic drug delivery.

151 Doxil, a liposomal formulation of the chemotherapeutic drug doxorubicin, is FDA-approved for m

152 st cancer cells to DNA damage induced by the chemotherapeutic drug doxorubicin.

153 ensitizer, and gemcitabine - an FDA approved chemotherapeutic drug for lung cancer chemo-radiotherapy

154 s, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycy

155 enhanced when BMTP-11 was combined with the chemotherapeutic drug gemcitabine.

156 erministic analysis of the success rate of a chemotherapeutic drug in less than 12h.

157 seeded in a 3D extra cellular matrix when a chemotherapeutic drug is flown next to the matrix.

158 Recurrence and chemotherapeutic drug resistance are two of the most pro

159 regulation of cell division and inducing the chemotherapeutic drug resistance.

160 nifying an important role of CAF exosomes in chemotherapeutic drug resistance.

161 ological processes, disease diagnostics, and chemotherapeutic drug screening.

162 Etoposide (ETO) is a commonly used chemotherapeutic drug that inhibits topoisomerase II act

163 c cytokine secretion and reduced the IC50 of chemotherapeutic drug treatments in AML cells.

164 Gemcitabine is a widely used chemotherapeutic drug, but limited therapeutic efficacy

165 er cells treated with ionizing radiation and chemotherapeutic drug, paclitaxel.

166 own activity for this widely utilized cancer chemotherapeutic drug.

167 om dose-limiting toxicity of streptozocin, a chemotherapeutic drug.

168 e more sensitive to doxorubicin, a classical chemotherapeutic drug.

169 The finding that cancer chemotherapeutic drugs and ionizing radiation often prom

170 eveloped laboratory biosensors for screening chemotherapeutic drugs and to aid in the assessment of D

171 Systemically administered chemotherapeutic drugs are often ineffective in the trea

172 Convection enhanced delivery (CED) of chemotherapeutic drugs can successfully bypass the blood

173 KK2 knockdown potentiated the effects of the chemotherapeutic drugs carboplatin and PX-866 to reduce

174 eficient cells; treatment of both lines with chemotherapeutic drugs elicited similar intrinsic apopto

175 have created a large arsenal of targeted and chemotherapeutic drugs for precision medicine.

176 dioisotopes into tumors for internal RIT, or chemotherapeutic drugs for synergistically combined chem

177 ployed to investigate the suitability of six chemotherapeutic drugs from the perspective of intratumo

178 Chemotherapeutic drugs have made significant contributio

179 We discovered that resistance to chemotherapeutic drugs in these lines broadly correlates

180 STRAP sensitized colorectal cancer cells to chemotherapeutic drugs in vitro and in vivo STRAP deplet

181 reduced the IC50 inhibitory concentration of chemotherapeutic drugs in vitro This MCAM-mediated sensi

182 Many chemotherapeutic drugs kill only a fraction of cancer ce

183 The effect of many contemporary chemotherapeutic drugs on pregnancy and livebirth is not

184 contribution of bacteria to the response to chemotherapeutic drugs remains poorly understood.

185 minating against devastating cytotoxicity of chemotherapeutic drugs to healthy cells.

186 (MTAs), widely used as biological probes and chemotherapeutic drugs, bind directly to tubulin subunit

187 differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the asse

188 ncer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide.

189 resistance (MDR) after prolonged exposure to chemotherapeutic drugs, which is a severe impediment to

190 ance (MDR) restricts the efficacy of current chemotherapeutic drugs.

191 of the efficacy and toxicity profile of the chemotherapeutic drugs.

192 ereas its deregulation reduces resistance to chemotherapeutic drugs.

193 (I.P./I.V.) injection alone or combined with chemotherapeutic drugs.

194 siRNA knockdown and following treatment with chemotherapeutic drugs.

195 dered them sensitive to apoptosis induced by chemotherapeutic drugs.

196 like receptors, reactive oxygen species, and chemotherapeutic drugs.

197 hich is upregulated following treatment with chemotherapeutic drugs.

198 in cancer cells, and thus sensitise them to chemotherapeutic drugs.

199 fection that is resistant to the majority of chemotherapeutic drugs.

200 ed G1 arrest and induced hypersensitivity to chemotherapeutic drugs.

201 which the HIV-1 reservoir may be limited by chemotherapeutic drugs.

202 screens in two bacterial species using three chemotherapeutic drugs: 5-fluorouracil (5-FU), 5-fluoro-

203 The change in impedance magnitude on flowing chemotherapeutics drugs measured at 12h for drug-suscept

204 ds of Pt(II) compounds that are required for chemotherapeutic efficacy and toxicity are no longer bou

205 ulate MDR gene expression in vivo to enhance chemotherapeutic efficacy by several orders of magnitude

206 cer, but the significance of these events to chemotherapeutic efficacy has not been examined deeply i

207 ergence of acquired resistance and augmented chemotherapeutic efficacy in both chemosensitive and che

208 ng to ERalpha reactivation and re-sensitized chemotherapeutic efficacy of anti-hormone therapy.

209 on into established tumors and enhancing the chemotherapeutic efficacy of drugs with poor BTB penetra

210 ocarrier formulation that can safely improve chemotherapeutic efficacy, address risks of drug resista

211 genetic approach rescues HSCs loss, promotes chemotherapeutic efficacy, and enhances survival.

212 esulting in regression of autophagy improves chemotherapeutic efficacy, thereby providing a new strat

213 an be a promising strategy for improving the chemotherapeutic efficiency of skin cancers.

214 Many cytotoxic chemotherapeutics elicit a proinflammatory response whic

215 he SK1-specific inhibitor SK1-I and standard chemotherapeutics, expression of CIB2 also sensitized ov

216 anomaterials show great potential to deliver chemotherapeutics for cancer treatment.

217 bromodomain inhibition was combined with the chemotherapeutic gemcitabine, pervasive apoptosis was ob

218 ing both naked and nanoparticle-encapsulated chemotherapeutics, genes, and radioisotopes.

219 anisms during the response to a conventional chemotherapeutic illustrates how inhibition of checkpoin

220 We also sought regulation of chemotherapeutics in cancer microenvironment towards phe

221 B, and Janus kinase, which are activated by chemotherapeutics in epithelial cell-transitioned prosta

222 single agents and in combination with other chemotherapeutics, in several subtypes of breast cancer

223 s induced synthetic lethality with genotoxic chemotherapeutics, including PARP inhibitors, and nongen

224 protection against the cytotoxic actions of chemotherapeutics, including reductions in oxidative str

225 ansplant capacity, and sensitizes animals to chemotherapeutic injury.

226 Successful chemotherapeutic intervention for management of lung can

227 Chemotherapeutic intervention of MDSCs has gained ground

228 the complexities by which tumour cells evade chemotherapeutic interventions and acquire drug resistan

229 Mabs infections, refractory to most standard chemotherapeutic interventions.

230 Unfortunately, the development of new chemotherapeutics is a long and costly process.

231 Although a vast repertoire of chemotherapeutics is currently available for treating ca

232 e clinical use of multiple classes of cancer chemotherapeutics is limited by irreversible, dose-depen

233 fective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenstr

234 d by proteotoxic agents and the proapoptotic chemotherapeutic LCL-161.

235 Inhibition of the Clec16a pathway by the chemotherapeutic lenalidomide, a selective ubiquitin lig

236 e bladder condition associated with systemic chemotherapeutics, like cyclophosphomide.

237 ing a modular platform for antibody directed chemotherapeutic nanoparticles.

238 Cancer chemotherapeutics often fail to reach all diseased cells

239 rch targeting mitochondria will provide more chemotherapeutic opportunities.

240 eta stimulation and therefore orients future chemotherapeutic opportunities.

241 ently used drugs accentuate the need for new chemotherapeutic options against severe malaria.

242 ly available antibiotics seriously restricts chemotherapeutic options.

243 Exposure to chemotherapeutic or biologic agents, prior liver therapi

244 Parasite control occurs through chemotherapeutic or immunologic means, which decrease or

245 ingle-agent or in combination therapies with chemotherapeutics or radiotherapy.

246 resistance of one FDA approved, widely used chemotherapeutic paclitaxel, may be promising direction

247 nistered simultaneously or subsequent to the chemotherapeutic paclitaxel; simultaneous treatment more

248 was to investigate the in vitro and ex vivo chemotherapeutic potential of double walled PLGA-chitosa

249 iffuse red marrow infiltration and extensive chemotherapeutic pretreatments are excluded, then treatm

250 In conclusion, PAIB-SOs are novel chemotherapeutic prodrugs with no equivalent among curre

251 The implications of using different chemotherapeutic regimens based on estrogen receptor and

252 agent to improve the efficacy of the current chemotherapeutic regimens for MM patients.

253 5-FU-based combinatory chemotherapeutic regimens have been routinely used for m

254 sion 1.1) previously treated with one or two chemotherapeutic regimens, including a platinum-based re

255 The efficient delivery of liposomal chemotherapeutics relies, however, on the enhanced perme

256 but optimal treatment strategies to overcome chemotherapeutic resistance and eliminate metastases hav

257 phenotypic diversity and drive selection for chemotherapeutic resistance and tumor relapse.

258 evidence for the role of oxidative stress in chemotherapeutic resistance in renal carcinoma cells pot

259 cular, compound 3b potently reduced in vitro chemotherapeutic resistance of 4T1 breast cancer stem-li

260 lls that had undergone EMT also had enhanced chemotherapeutic resistance, with a higher half-maximal

261 erimental/computational approach to evaluate chemotherapeutic response combined with RF-induced pheno

262 roperties were incorporated to determine the chemotherapeutic response in cancer patients.

263 ecently been shown to play decisive roles in chemotherapeutic response.

264 utophagy pathway and alter colorectal cancer chemotherapeutic response.

265 esion DNA synthesis as a strategy to improve chemotherapeutic responses in aggressive brain tumors.Si

266 supports the concept of designing different chemotherapeutic schedules for tumors with different gro

267 Defective fork stability contributes to chemotherapeutic sensitivity of BRCA2-defective tumors b

268 y degraded by the MRE11 nuclease, leading to chemotherapeutic sensitivity.

269 t in response to UV irradiation or genotoxic chemotherapeutics, SOX9 is actively degraded in various

270 intrinsically resistant to gemcitabine, the chemotherapeutic standard of care for PDAC.

271 The current chemotherapeutic strategies against localized and metast

272 velopment of predictive biomarkers and novel chemotherapeutic strategies for paclitaxel resistance.

273 oretic cell-cell interaction model to design chemotherapeutic strategies tailored to different tumor

274 s followed by DTX regime provide a promising chemotherapeutic strategy and its significant role for t

275 ot-hydrogel for evaluating the efficacy of a chemotherapeutic substance, underscoring the potential o

276 nd is differentiated from other DNA-targeted chemotherapeutics such as cisplatin by its potency, cell

277 e that is resistant to many standard of care chemotherapeutics such as cisplatin.

278 e oleandrin as a coadjuvant drug to standard chemotherapeutics such as temozolomide.

279 lexes as viable alternatives to conventional chemotherapeutics, such as cisplatin.

280 perature-sensitive liposomal formulations of chemotherapeutics, such as doxorubicin, can achieve loca

281 re proficient at metastatic colonization and chemotherapeutic survival.

282 ruzi, is an important virulence factor and a chemotherapeutic target with excellent pre-clinical vali

283 show pairing a potent cytotoxic nanoparticle chemotherapeutic that complements and improves concurren

284 y similar to ICRF-187, a clinically approved chemotherapeutic that stabilizes an ATP-dependent dimeri

285 late BRCA2-deficient cancer cell response to chemotherapeutics that cause fork degradation.BRCA prote

286 rain alone or in combination with a clinical chemotherapeutic to a syngeneic mouse transplantation mo

287 concept for a method to enhance delivery of chemotherapeutics to breast cancer cells within the bone

288 ker informing on individual sensitivities to chemotherapeutic Top2 poisons.

289 ful indicator of a cancer cell's response to chemotherapeutic treatment and should improve our unders

290 ities to evade cell death induced by current chemotherapeutic treatment approaches.

291 shell nanoparticles promise a more effective chemotherapeutic treatment for many challenging cancers.

292 port proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overco

293 This therapy might be a non-chemotherapeutic treatment option for patients with Wald

294 ency on cellular responses to DNA damage and chemotherapeutic treatment remains unclear.

295 model exhibited the most robust response to chemotherapeutic treatment, and possessed the greatest c

296 nd may facilitate leukemia relapse following chemotherapeutic treatment.

297 PEGylated liposomes have transformed chemotherapeutic use of doxorubicin by reducing its card

298 enoid indole alkaloids (TIAs), including the chemotherapeutics, vincristine and vinblastine.

299 we evaluated it in combination with Taxol, a chemotherapeutic with activity in both diseases.

300 carboxylated gallium corroles are promising chemotherapeutics with the advantage that they also can